KR101528970B1 - 항체의 농축 방법 및 이의 치료용 생성물 - Google Patents

항체의 농축 방법 및 이의 치료용 생성물 Download PDF

Info

Publication number
KR101528970B1
KR101528970B1 KR1020127030933A KR20127030933A KR101528970B1 KR 101528970 B1 KR101528970 B1 KR 101528970B1 KR 1020127030933 A KR1020127030933 A KR 1020127030933A KR 20127030933 A KR20127030933 A KR 20127030933A KR 101528970 B1 KR101528970 B1 KR 101528970B1
Authority
KR
South Korea
Prior art keywords
antibody
ultrafiltration
concentration
buffer
pool
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020127030933A
Other languages
English (en)
Korean (ko)
Other versions
KR20120135530A (ko
KR101528970B9 (ko
Inventor
찰스 매튜 윈터
Original Assignee
제넨테크, 인크.
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101528970(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 제넨테크, 인크., 노파르티스 아게 filed Critical 제넨테크, 인크.
Publication of KR20120135530A publication Critical patent/KR20120135530A/ko
Application granted granted Critical
Publication of KR101528970B1 publication Critical patent/KR101528970B1/ko
Publication of KR101528970B9 publication Critical patent/KR101528970B9/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
KR1020127030933A 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물 Expired - Lifetime KR101528970B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US60/609,092 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof
US11/220,362 2005-09-06
KR1020077007862A KR20070109975A (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077007862A Division KR20070109975A (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Publications (3)

Publication Number Publication Date
KR20120135530A KR20120135530A (ko) 2012-12-14
KR101528970B1 true KR101528970B1 (ko) 2015-06-15
KR101528970B9 KR101528970B9 (ko) 2022-12-09

Family

ID=35996499

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127030933A Expired - Lifetime KR101528970B1 (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물
KR1020077007862A Ceased KR20070109975A (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077007862A Ceased KR20070109975A (ko) 2004-09-09 2005-09-08 항체의 농축 방법 및 이의 치료용 생성물

Country Status (32)

Country Link
US (6) US20060051347A1 (enExample)
EP (5) EP4108259B1 (enExample)
JP (2) JP5210633B2 (enExample)
KR (2) KR101528970B1 (enExample)
CN (3) CN101056885B (enExample)
AR (1) AR050641A1 (enExample)
AU (1) AU2005285243C1 (enExample)
BR (1) BRPI0515649B8 (enExample)
CA (1) CA2577317C (enExample)
DK (5) DK4104859T3 (enExample)
EC (1) ECSP077282A (enExample)
ES (5) ES2975166T3 (enExample)
FI (4) FI4104859T3 (enExample)
GT (1) GT200500254A (enExample)
HU (4) HUE067662T2 (enExample)
IL (2) IL181372A (enExample)
LT (4) LT4108259T (enExample)
MA (1) MA28991B1 (enExample)
MX (2) MX342788B (enExample)
MY (2) MY162525A (enExample)
NO (1) NO333660B1 (enExample)
NZ (1) NZ553239A (enExample)
PE (1) PE20060816A1 (enExample)
PL (5) PL4104859T3 (enExample)
PT (5) PT1786830E (enExample)
RU (1) RU2390524C2 (enExample)
SG (1) SG177161A1 (enExample)
SI (5) SI3805248T1 (enExample)
TN (1) TNSN07069A1 (enExample)
TW (1) TWI372630B (enExample)
WO (1) WO2006031560A2 (enExample)
ZA (1) ZA200701626B (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
DK1758558T3 (da) 2004-05-12 2014-01-20 Baxter Int Oligonukleotidholdige mikrokugler samt deres anvendelse til fremstilling af et medikament til behandling af diabetes type 1
DK1765294T3 (da) 2004-05-12 2008-11-10 Baxter Int Nukleinsyremikrokugler samt deres fremstilling og afgivelse
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
DK2007506T3 (da) * 2006-03-31 2014-06-16 Danisco Us Inc Tangentialstrømningsfiltreringsapparater, -systemer og -fremgangsmådertil separering af forbindelser
ES2744499T3 (es) * 2006-04-04 2020-02-25 Chiesi Farm Spa Un proceso para la concentración de un polipéptido
AU2008233173B2 (en) 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
AU2008277886B8 (en) * 2007-07-17 2013-08-01 F. Hoffmann-La Roche Ag Variable tangential flow filtration
JP5205470B2 (ja) * 2007-11-29 2013-06-05 エフ．ホフマン−ラ ロシュ アーゲー 免疫グロブリン凝集物
TWI543768B (zh) * 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) * 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8772461B2 (en) * 2008-04-15 2014-07-08 Grifols Therapeutics Inc. Two-stage ultrafiltration/diafiltration
JP5762951B2 (ja) * 2008-05-15 2015-08-12 ダブリュ．・ヘルス・エル．ピー．Ｗ． Ｈｅａｌｔｈ Ｌ．Ｐ． 分泌性免疫グロブリンの豊富な乳画分の製造方法
CN102245206A (zh) * 2008-12-09 2011-11-16 弗·哈夫曼-拉罗切有限公司 获得无赋形剂抗体溶液的方法
WO2010090864A2 (en) * 2009-01-21 2010-08-12 Smartflow Technologies, Inc. Optimization of separation for viscous suspensions
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
US9586180B2 (en) * 2009-03-24 2017-03-07 Wyeth Llc Membrane evaporation for generating highly concentrated protein therapeutics
JP5341252B2 (ja) * 2009-05-27 2013-11-13 バクスター・インターナショナル・インコーポレイテッド 皮下使用の高濃度免疫グロブリン製剤を生成する方法
HUE029197T2 (en) * 2009-09-29 2017-02-28 Hoffmann La Roche Adjustment of dissolved buffer by pre-filtration to a high concentration immunoglobulin formulation
KR101718301B1 (ko) 2009-10-01 2017-03-20 에프. 호프만-라 로슈 아게 다단계 최종 여과
DK2531218T3 (en) 2010-02-04 2019-04-01 Csl Behring Ag immunoglobulin
AU2011223710B2 (en) 2010-03-01 2016-04-14 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2729566B1 (en) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
JP6363017B2 (ja) 2011-09-01 2018-07-25 中外製薬株式会社 限外ろ過によって高度に濃縮された抗体を含む組成物を調製するための方法
WO2013096791A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Process for making high concentration protein formulations
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP2016504344A (ja) * 2012-12-28 2016-02-12 ノヴォ ノルディスク アー／エス 高温デッドエンド抗体ろ過
EP2943568B1 (en) 2013-01-09 2019-11-20 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
CN112588116A (zh) 2014-05-13 2021-04-02 美国安进公司 用于过滤器和过滤过程的过程控制系统和方法
WO2015195452A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Single-pass filtration systems and processes
EP2957335B1 (en) * 2014-06-16 2020-05-27 EMD Millipore Corporation Single-pass filtration systems and processes
EP4144434B1 (en) * 2014-06-16 2024-04-17 EMD Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
KR101938948B1 (ko) 2014-06-25 2019-01-15 이엠디 밀리포어 코포레이션 밀집한 나권형 필터 엘리먼트, 모듈 및 시스템
WO2016033546A1 (en) 2014-08-29 2016-03-03 Emd Millipore Corporation Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
WO2016033553A1 (en) 2014-08-29 2016-03-03 Emd Millipore Corporation Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
CN114569716A (zh) 2014-10-23 2022-06-03 美国安进公司 降低药物制剂的粘度
JP6726666B2 (ja) 2014-12-03 2020-07-22 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 免疫グロブリンを含む安定性が高められた医薬製品
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
HK1255006A1 (zh) * 2015-09-22 2019-08-02 Pfizer Inc. 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂
US12226737B2 (en) 2016-06-09 2025-02-18 Emd Millipore Corporation Radial-path filter elements, systems and methods of using same
EP3500589B1 (en) * 2016-08-16 2022-05-04 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
JP7114567B2 (ja) 2016-08-17 2022-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 生体分子を含む高濃縮液体製剤の調製のためのプロセス
WO2018075818A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
KR102754228B1 (ko) * 2017-12-27 2025-01-14 (주)셀트리온 투석 여과 방법
CN111971302A (zh) * 2018-04-12 2020-11-20 美国安进公司 制备稳定的蛋白质组合物的方法
TWI898645B (zh) 2018-05-04 2025-09-21 美商健臻公司 灌注式細胞培養裝置
CA3108693A1 (en) * 2018-08-10 2020-02-13 Ashutosh Sharma Method of preparing an antibody pharmaceutical formulation
EP3837273B1 (en) 2018-08-14 2025-09-24 Bristol-Myers Squibb Company Improved protein recovery
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
US20220119757A1 (en) * 2019-02-15 2022-04-21 Just-Evotec Biologics, Inc. Automated biomanufacturing systems, facilities, and processes
DK3791395T3 (da) * 2019-07-31 2021-09-13 Catalent Uk Swindon Zydis Ltd Densitetsgennemstrømningsmåler til dosering af farmaceutisk formulering
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
EP4225770A1 (en) * 2020-10-05 2023-08-16 Bristol-Myers Squibb Company Methods for concentrating proteins
BR112023009620A2 (pt) 2020-11-23 2023-12-12 Abec Inc Sistemas, componentes e métodos de filtragem
JP7667300B2 (ja) * 2021-03-08 2025-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シングルパス向流透析濾過のためのシステム及び方法
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
JP2025507625A (ja) 2022-02-25 2025-03-21 アムジエン・インコーポレーテツド 高濃度の液体原薬を調製する方法
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩系统及其工艺
IL318205A (en) * 2022-07-12 2025-03-01 Beigene Switzerland Gmbh Method for preparing a highly concentrated solution of anti-PD1 antibody using ultrafiltration/diafiltration (UF/DF)
CN115873064A (zh) * 2022-09-27 2023-03-31 英脉生物医药(杭州)有限公司 高浓度蛋白样品的制备装置及方法
WO2024224337A1 (en) * 2023-04-25 2024-10-31 Enzene Biosciences Limited In line cleaning in place process for alternating tangential flow filter
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies
CA3237624A1 (en) 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004042012A2 (en) * 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
US20040167320A1 (en) * 2003-02-24 2004-08-26 Couto Daniel E. Methods of tangential flow filtration and an apparatus therefore

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (enExample) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IN161706B (enExample) 1983-10-05 1988-01-16 Solco Basel Ag
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB2218703B (en) 1988-05-10 1992-10-28 Sumitomo Chemical Co Human monoclonal antibody to p.aeruginosa: its production and use
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU4803890A (en) 1988-12-15 1990-07-10 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
KR20010030665A (ko) * 1997-09-22 2001-04-16 세프라겐 코포레이션 유장 단백질의 순차적 분리법 및 그의 제제
RU2140287C1 (ru) * 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
WO2000024266A2 (en) 1998-10-26 2000-05-04 Galagen, Inc. Soy and immunoglobulin compositions
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
AU5719600A (en) 1999-07-07 2001-01-30 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
EP2311492B1 (en) * 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
JP2005521640A (ja) * 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Ａｐｏ−２リガンド／ＴＲＡＩＬ製剤
EP1478394B1 (en) 2002-02-27 2008-07-30 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
EP1551875A4 (en) * 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
JP2008500959A (ja) 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
US20080247991A1 (en) 2004-02-26 2008-10-09 Trout Bernhardt L Solution Additives For the Attenuation of Protein Aggregation
WO2006018956A1 (ja) 2004-08-19 2006-02-23 Electronic Navigation Research Institute, An Independent Administrative Institution 誘電体レンズを用いた装置
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法
WO2019035815A1 (en) 2017-08-16 2019-02-21 O&M Halyard International Unlimited Company METHOD AND SYSTEM FOR FASTENING ATTACHES IN A METHOD FOR MANUFACTURING FACIAL MASKS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004042012A2 (en) * 2002-11-01 2004-05-21 Bayer Healthcare Llc Process for concentration of macromolecules
US20040167320A1 (en) * 2003-02-24 2004-08-26 Couto Daniel E. Methods of tangential flow filtration and an apparatus therefore

Also Published As

Publication number Publication date
PL4108259T3 (pl) 2024-05-13
NO333660B1 (no) 2013-08-05
AU2005285243C1 (en) 2012-10-25
US11767370B2 (en) 2023-09-26
FI3805248T3 (fi) 2023-04-21
SI3805248T1 (sl) 2023-05-31
PE20060816A1 (es) 2006-09-02
NZ553239A (en) 2009-11-27
RU2390524C2 (ru) 2010-05-27
WO2006031560A3 (en) 2006-08-24
JP5210633B2 (ja) 2013-06-12
US12371510B2 (en) 2025-07-29
IL181372A (en) 2012-01-31
PL2292636T3 (pl) 2024-03-11
US20060051347A1 (en) 2006-03-09
BRPI0515649B8 (pt) 2021-11-03
BRPI0515649A (pt) 2008-07-29
EP4108259B1 (en) 2024-01-03
EP3805248B1 (en) 2023-01-18
HK1215869A1 (zh) 2016-09-23
PL4104859T3 (pl) 2024-08-26
DK2292636T3 (da) 2024-01-15
DK4104859T3 (da) 2024-07-08
HUE067296T2 (hu) 2024-10-28
HUE067662T2 (hu) 2024-11-28
HK1101249A1 (en) 2007-10-12
CA2577317A1 (en) 2006-03-23
EP2292636A3 (en) 2013-05-01
CN104961797A (zh) 2015-10-07
US20140370003A1 (en) 2014-12-18
EP1786830A2 (en) 2007-05-23
ZA200701626B (en) 2008-10-29
ES2942574T3 (es) 2023-06-02
NO20071432L (no) 2007-03-16
JP2008512473A (ja) 2008-04-24
AU2005285243B2 (en) 2012-03-08
PT3805248T (pt) 2023-04-05
EP3805248A3 (en) 2021-07-14
PT4104859T (pt) 2024-07-02
FI2292636T3 (fi) 2024-01-12
TNSN07069A1 (en) 2008-06-02
MX342788B (es) 2016-10-12
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
MA28991B1 (fr) 2007-11-01
IL181372A0 (en) 2007-07-04
CN102911268A (zh) 2013-02-06
DK1786830T3 (en) 2015-01-19
LT4104859T (lt) 2024-07-10
HUE061899T2 (hu) 2023-08-28
DK4108259T3 (da) 2024-03-11
SI4108259T1 (sl) 2024-04-30
IL216851A0 (en) 2012-01-31
DK3805248T3 (da) 2023-04-03
KR20120135530A (ko) 2012-12-14
SI4104859T1 (sl) 2024-08-30
EP4104859A1 (en) 2022-12-21
FI4104859T3 (fi) 2024-07-16
ES2983099T3 (es) 2024-10-22
CA2577317C (en) 2016-04-26
US20090214522A1 (en) 2009-08-27
ES2528541T3 (es) 2015-02-10
TWI372630B (en) 2012-09-21
US20230074486A1 (en) 2023-03-09
JP5426641B2 (ja) 2014-02-26
PT1786830E (pt) 2015-02-05
SG177161A1 (en) 2012-01-30
EP4108259A1 (en) 2022-12-28
ECSP077282A (es) 2007-03-29
TW200612989A (en) 2006-05-01
LT4108259T (lt) 2024-04-10
CN101056885A (zh) 2007-10-17
FI4108259T3 (fi) 2024-09-10
AU2005285243A1 (en) 2006-03-23
EP2292636B1 (en) 2023-10-18
PL3805248T3 (pl) 2023-05-22
CN101056885B (zh) 2015-08-26
EP3805248A2 (en) 2021-04-14
GT200500254A (es) 2006-08-02
EP2292636A2 (en) 2011-03-09
SI2292636T1 (sl) 2024-02-29
AR050641A1 (es) 2006-11-08
ES2975166T3 (es) 2024-07-03
JP2012097086A (ja) 2012-05-24
EP1786830B1 (en) 2014-11-12
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
KR101528970B9 (ko) 2022-12-09
ES2968070T3 (es) 2024-05-07
HUE065025T2 (hu) 2024-04-28
PT4108259T (pt) 2024-03-07
CN104961797B (zh) 2020-12-25
MX2007002812A (es) 2007-05-16
MY150549A (en) 2014-01-30
US10370456B2 (en) 2019-08-06
MY162525A (en) 2017-06-15
EP2292636B9 (en) 2024-01-03
PL1786830T3 (pl) 2015-05-29
US20070237762A1 (en) 2007-10-11
WO2006031560A2 (en) 2006-03-23
LT3805248T (lt) 2023-04-25
DK3805248T5 (da) 2023-04-24
KR20070109975A (ko) 2007-11-15
SI1786830T1 (sl) 2015-03-31
EP4104859B1 (en) 2024-04-17
BRPI0515649B1 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
KR101528970B1 (ko) 항체의 농축 방법 및 이의 치료용 생성물
HK40047421A (en) Process for concentration of antibodies and therapeutic products thereof
HK40047421B (en) Process for concentration of antibodies and therapeutic products thereof
HK1215869B (zh) 濃縮抗體的方法及其治療性產品
HK1101249B (en) Process for concentration of antibodies and therapeutic products thereof
HK40083042A (en) Process for concentration of antibodies and therapeutic products thereof
HK1155186A (en) Process for concentration of antibodies and therapeutic products thereof
HK40084343B (en) Process for concentration of antibodies and therapeutic products thereof
HK40084343A (en) Process for concentration of antibodies and therapeutic products thereof
HK1155186B (en) Process for concentration of antibodies and therapeutic products thereof
HK40083042B (en) Process for concentration of antibodies and therapeutic products thereof
HK1178178A (en) Process for concentration of antibodies and therapeutic products thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20121126

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20121224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150327

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150609

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 7

End annual number: 7

J202 Request for trial for correction [limitation]
PJ0202 Trial for correction

Comment text: Request for Trial

Patent event date: 20221004

Patent event code: PJ02022R01D

Comment text: Registration of Establishment

Patent event date: 20150609

Patent event code: PJ02021E01I

Appeal kind category: Correction

Request date: 20221004

Appeal identifier: 2022105000085

J301 Trial decision

Free format text: TRIAL NUMBER: 2022105000085; TRIAL DECISION FOR CORRECTION REQUESTED 20221004

Effective date: 20221123

PJ1301 Trial decision

Patent event code: PJ13011S03D

Patent event date: 20221123

Comment text: Trial Decision on Correction (Patent, Utility Model)

Appeal kind category: Correction

Request date: 20221004

Decision date: 20221123

Appeal identifier: 2022105000085

PG1701 Publication of correction

Publication date: 20221209

PR1001 Payment of annual fee

Payment date: 20230327

Start annual number: 9

End annual number: 9

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

Patent event code: PJ02062R01D

Patent event date: 20230601

Comment text: Request for Trial

Patent event code: PJ02061E01I

Patent event date: 20150609

Comment text: Registration of Establishment

Request date: 20230601

Appeal identifier: 2023100001971

Appeal kind category: Confirmation of the scope of right_affirmative

PR1001 Payment of annual fee

Payment date: 20240527

Start annual number: 10

End annual number: 10

J301 Trial decision

Free format text: TRIAL NUMBER: 2023100001971; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_AFFIRMATIVE REQUESTED 20230601

Effective date: 20240628

PJ1301 Trial decision

Patent event code: PJ13011S02D

Patent event date: 20240628

Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design)

Appeal kind category: Confirmation of the scope of right_affirmative

Request date: 20230601

Decision date: 20240628

Appeal identifier: 2023100001971

J121 Written withdrawal of request for trial
PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20240730

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2023100001971

Request date: 20230601

Appeal kind category: Confirmation of the scope of right_affirmative

Decision date: 20240628